Drug Profile


Alternative Names: LUZ-11

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator Bluepharma; Universidade de Coimbra
  • Developer Luzitin
  • Class Antineoplastics; Macrocyclic compounds; Porphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 15 Mar 2016 Phase-II clinical trials in Head and neck cancer in Portugal (IV)
  • 20 Feb 2014 Phase-I/II clinical trials in Head and neck cancer in Portugal (IV)
  • 08 Dec 2012 Luzitin licensed patents by Bluepharma and Universidade de Coimbra
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top